A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage medical device company focused on designing, developing and marketing advanced laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Our current systems, the LENSAR Laser System, or LLS, and ALLY Robotic Cataract Laser System™, or ALLY System, or collectively, the Systems, incorporate a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision. We believe the cumulative effect of these technologies results in laser systems that can be quickly and efficiently integrated into a surgeon’s existing practice, is easy to use and provides surgeons the ability to deliver improved visual outcomes with enhanced precision and the ability to do so consistently.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 59M | 53M | 42M | 35M | 34M | 26M |
| Net Income | -52M | -31M | -14M | -20M | -20M | -20M |
| EPS | $-4.37 | $-2.73 | $-1.31 | $-1.96 | $-2.09 | $-4.28 |
| Free Cash Flow | -12M | -2.4M | -9.9M | -15M | -9.3M | -14M |
| ROIC | -23.6% | -173.3% | -43.0% | -47.4% | -35.7% | -29.4% |
| Gross Margin | 46.1% | 48.3% | 50.1% | 56.4% | 51.8% | 53.4% |
| Debt/Equity | 0.00 | 9.80 | 0.67 | 0.33 | 0.21 | 0.18 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -21M | -11M | -12M | -20M | -20M | -19M |
| Operating Margin | -35.4% | -19.9% | -29.0% | -57.1% | -57.0% | -70.1% |
| ROE | 0.0% | -164.0% | -38.1% | -41.1% | -32.1% | -107.9% |
| Shares Outstanding | 12M | 12M | 11M | 10M | 9M | 11M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 31M | 26M | 34M | 35M | 42M | 53M | 59M |
| Gross Margin | 43.3% | 53.4% | 51.8% | 56.4% | 50.1% | 48.3% | 46.1% |
| R&D | 7.6M | 7.6M | 12M | 12M | 6.1M | 5.3M | 5.7M |
| SG&A | 17M | 24M | 24M | 27M | 26M | 26M | 42M |
| EBIT | -13M | -19M | -20M | -20M | -12M | -11M | -21M |
| Op. Margin | -41.6% | -70.1% | -57.0% | -57.1% | -29.0% | -19.9% | -35.4% |
| Net Income | -15M | -20M | -20M | -20M | -14M | -31M | -52M |
| Net Margin | -48.0% | -75.0% | -56.9% | -56.3% | -34.1% | -58.7% | -87.1% |
| Non-Recurring | 0 | -19K | 131K | 39K | 59K | 94K | 0 |
| Returns on Capital | |||||||
| ROIC | -36.8% | -29.4% | -35.7% | -47.4% | -43.0% | -173.3% | -23.6% |
| ROE | N/A | -107.9% | -32.1% | -41.1% | -38.1% | -164.0% | 0.0% |
| ROA | -42.4% | -34.8% | -26.9% | -32.6% | -22.9% | -46.2% | -73.4% |
| Cash Flow | |||||||
| Op. Cash Flow | -13M | -14M | -9.0M | -15M | -9.7M | -2.3M | -12M |
| Free Cash Flow | -13M | -14M | -9.3M | -15M | -9.9M | -2.4M | -12M |
| Owner Earnings | -14M | -25M | -18M | -24M | -18M | -7.3M | -18M |
| CapEx | 389K | 366K | 354K | 115K | 236K | 156K | 86K |
| Maint. CapEx | 1.5M | 1.9M | 1.9M | 2.2M | 2.4M | 2.4M | 3.5M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 1.5M | 1.9M | 1.9M | 2.2M | 2.4M | 2.4M | 3.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 102K | 9.0M | 6.9M | 6.6M | 5.5M | 2.7M | 2.9M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -17M |
| Cash & Equiv. | 4.6M | 41M | 32M | 15M | 21M | 16M | 17M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -2.13 | 0.18 | 0.21 | 0.33 | 0.67 | 9.80 | 0.00 |
| Interest Coverage | -6.4 | -13.8 | -14.7 | N/A | N/A | N/A | N/A |
| Equity | -31M | 67M | 55M | 42M | 33M | 4.9M | -26M |
| Total Assets | 35M | 79M | 66M | 56M | 70M | 66M | 70M |
| Total Liabilities | 65M | 12M | 12M | 14M | 22M | 48M | 82M |
| Intangibles | 17M | 19M | 17M | 18M | 17M | 12M | 5.4M |
| Retained Earnings | -38M | -58M | -78M | -98M | -112M | -143M | -176M |
| Working Capital | 9.4M | 50M | 36M | 22M | 35M | 27M | 8.7M |
| Current Assets | 17M | 58M | 45M | 34M | 46M | 42M | 44M |
| Current Liabilities | 7.8M | 8.5M | 8.7M | 11M | 12M | 15M | 36M |
| Per Share Data | |||||||
| EPS | -13.70 | -4.28 | -2.09 | -1.96 | -1.31 | -2.73 | -4.37 |
| Owner EPS | -13.30 | -2.26 | -1.90 | -2.33 | -1.60 | -0.64 | -1.53 |
| Book Value | -28.56 | 6.15 | 5.85 | 4.13 | 3.04 | 0.42 | -2.17 |
| Cash Flow/Share | -11.77 | -1.26 | -0.96 | -1.46 | -0.88 | -0.20 | -4.02 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.1M | 10.9M | 9.4M | 10.2M | 11.0M | 11.5M | 11.9M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -1.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.5 | 1.0 | 0.7 | 1.1 | 19.8 | N/A |
| Price/Sales | N/A | 1.8 | 2.4 | 2.0 | 0.9 | 1.2 | 1.2 |
| FCF Yield | N/A | -44.4% | -16.7% | -53.6% | -27.7% | -2.5% | -16.5% |
| Market Cap | N/A | 32M | 56M | 28M | 36M | 96M | 72M |
| Avg. Price | N/A | 8.66 | 7.67 | 5.88 | 2.94 | 4.78 | 6.04 |
| Year-End Price | N/A | 6.90 | 5.95 | 2.75 | 3.25 | 8.38 | 6.04 |
LENSAR, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 52.0%.
LENSAR, Inc. (LNSR) has a 5-year average return on invested capital (ROIC) of -65.8%. This is below average and may indicate limited pricing power.
LENSAR, Inc. (LNSR) has a market capitalization of $72M. It is classified as a small-cap stock.
LENSAR, Inc. (LNSR) does not currently pay a regular dividend.
LENSAR, Inc. (LNSR) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
LENSAR, Inc. (LNSR) reported annual revenue of $53 million in its most recent fiscal year, based on SEC EDGAR filings.
LENSAR, Inc. (LNSR) has a net profit margin of -58.7%. The company is currently unprofitable.
LENSAR, Inc. (LNSR) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
LENSAR, Inc. (LNSR) has a debt-to-equity ratio of 9.80. This indicates higher leverage, which may increase financial risk.
LENSAR, Inc. (LNSR) reported earnings per share (EPS) of $-2.73 in its most recent fiscal year.
LENSAR, Inc. (LNSR) has a return on equity (ROE) of -164.0%. A negative ROE may indicate losses or negative equity.
LENSAR, Inc. (LNSR) has a 5-year average gross margin of 52.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for LENSAR, Inc. (LNSR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LENSAR, Inc. (LNSR) has a book value per share of $0.42, based on its most recent annual SEC filing.